Trial Profile
An Observational, Multicentre, Prospective, Post Marketing Surveillance study to evaluate safety and efficacy of ELORESTM (Ceftriaxone, Sulbactam and Disodium Edetate) in patients with various bacterial infections (Labeled indications).
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Ceftriaxone/disodium edetate/sulbactam (Primary)
- Indications Bacterial infections; Gram-negative infections; Otitis media; Pneumococcal infections; Pyelonephritis; Respiratory tract infections; Skin and soft tissue infections
- Focus Adverse reactions
- Sponsors Venus Remedies
- 04 Jul 2013 New trial record